BioNxt Solutions Inc. (OTCMKTS:BNXTF – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 3,000 shares, an increase of 200.0% from the October 15th total of 1,000 shares. Based on an average trading volume of 10,902 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.0% of the shares of the company are sold short.
BioNxt Solutions Price Performance
BNXTF opened at $0.15 on Friday. The stock’s 50 day moving average price is $0.23 and its 200 day moving average price is $0.30. The stock has a market cap of $20.95 million, a P/E ratio of -3.08 and a beta of 0.85. BioNxt Solutions has a 12 month low of $0.10 and a 12 month high of $0.57.
BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) last announced its quarterly earnings results on Friday, August 28th. The company reported ($0.01) earnings per share (EPS) for the quarter.
About BioNxt Solutions
BioNxt Solutions Inc. is a Canadian life sciences company focused on developing pharmaceutical and diagnostic products using alternative drug-delivery technologies. Its platform work includes orally dissolvable films, transdermal delivery systems and related formulations intended to improve the convenience, dosing and absorption of established medicines. The company’s development programs have included therapies for neurological and other medical conditions, as well as diagnostic applications. BioNxt has emphasized the development, testing and potential commercialization of products through a combination of internal research and collaborations with external laboratories and manufacturing partners.
Featured Stories
- Five stocks we like better than BioNxt Solutions
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for BioNxt Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNxt Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
